RXR部分激动剂CBt-PMN对2型糖尿病具有治疗作用，且无RXR完全激动剂的副作用。
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
作者信息
Kakuta Hiroki, Yakushiji Nobumasa, Shinozaki Ryosuke, Ohsawa Fuminori, Yamada Shoya, Ohta Yui, Kawata Kohei, Nakayama Mariko, Hagaya Manabu, Fujiwara Chisa, Makishima Makoto, Uno Shigeyuki, Tai Akihiro, Maehara Ami, Nakayama Masaru, Oohashi Toshitaka, Yasui Hiroyuki, Yoshikawa Yutaka
机构信息
Division of Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , 1-1-1 Tsushima-Naka, Okayama 700-8530, Japan.
Division of Biochemistry, Department of Biomedical Sciences, Nihon University School of Medicine , 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.
出版信息
ACS Med Chem Lett. 2012 Apr 9;3(5):427-32. doi: 10.1021/ml300055n. eCollection 2012 May 10.
Abstract
Treating insulin resistance and type 2 diabetes in rodents, currently known retinoid X receptor (RXR) agonists induce significant adverse effects. Here we introduce a novel RXR partial agonist CBt-PMN (11b), which shows a potent glucose-lowering effect and improvements of insulin secretion and glucose tolerance without the serious adverse effects caused by RXR full agonists. We suggest that RXR partial agonists may be a new class of antitype 2 diabetes drug candidates.
摘要
在啮齿动物中治疗胰岛素抵抗和2型糖尿病时，目前已知的视黄酸X受体（RXR）激动剂会引发显著的不良反应。在此，我们介绍一种新型的RXR部分激动剂CBt-PMN（11b），它具有强效的降糖作用，能改善胰岛素分泌和葡萄糖耐量，且不会产生RXR完全激动剂所引起的严重不良反应。我们认为RXR部分激动剂可能是一类新型的抗2型糖尿病候选药物。
相似文献
1
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
ACS Med Chem Lett. 2012 Apr 9;3(5):427-32. doi: 10.1021/ml300055n. eCollection 2012 May 10.
2
Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.
J Med Chem. 2013 Mar 14;56(5):1865-77. doi: 10.1021/jm400033f. Epub 2013 Feb 20.
3
RXR partial agonist produced by side chain repositioning of alkoxy RXR full agonist retains antitype 2 diabetes activity without the adverse effects.
J Med Chem. 2015 Jan 22;58(2):912-26. doi: 10.1021/jm501863r. Epub 2014 Dec 17.
4
A partial agonist for retinoid X receptor mitigates experimental colitis.
Int Immunol. 2019 Mar 28;31(4):251-262. doi: 10.1093/intimm/dxy089.
5
Retinoid X Receptor Ligands with Anti-Type 2 Diabetic Activity.
Curr Top Med Chem. 2017;17(6):696-707. doi: 10.2174/1568026616666160617085545.
6
[Challenge of creating single-agents for the treatment of type 1 and 2 diabetes by targeting retinoid X receptor].
Yakugaku Zasshi. 2011;131(6):917-23. doi: 10.1248/yakushi.131.917.
7
Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes.
Endocrinology. 2006 Feb;147(2):1044-53. doi: 10.1210/en.2005-0690. Epub 2005 Nov 3.
8
Retinoid X receptor ligands: a patent review (2007 - 2013).
Expert Opin Ther Pat. 2014 Apr;24(4):443-52. doi: 10.1517/13543776.2014.880692. Epub 2014 Jan 24.
9
Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists.
Nature. 1997 Mar 27;386(6623):407-10. doi: 10.1038/386407a0.
10
Nuclear hormone retinoid X receptor (RXR) negatively regulates the glucose-stimulated insulin secretion of pancreatic ß-cells.
Diabetes. 2010 Nov;59(11):2854-61. doi: 10.2337/db09-1897. Epub 2010 Aug 26.
引用本文的文献
1
Comparative Evaluation and Profiling of Chemical Tools for the Nuclear Hormone Receptor Family 2.
ACS Pharmacol Transl Sci. 2025 Mar 14;8(3):854-870. doi: 10.1021/acsptsci.4c00719. Epub 2025 Feb 20.
2
Applications of palladium-catalyzed C-N cross-coupling reactions in pharmaceutical compounds.
RSC Adv. 2023 Jun 20;13(27):18715-18733. doi: 10.1039/d2ra07412e. eCollection 2023 Jun 15.
3
Ligand Screening System for the RXRα Heterodimer Using the Fluorescence RXR Agonist CU-6PMN.
ACS Med Chem Lett. 2023 Feb 20;14(3):291-296. doi: 10.1021/acsmedchemlett.2c00509. eCollection 2023 Mar 9.
4
An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.
Int J Mol Sci. 2022 Dec 19;23(24):16213. doi: 10.3390/ijms232416213.
5
Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB).
Int J Mol Sci. 2021 Nov 16;22(22):12371. doi: 10.3390/ijms222212371.
6
The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer.
Sci Rep. 2020 Dec 17;10(1):22244. doi: 10.1038/s41598-020-79260-8.
7
A review of the molecular design and biological activities of RXR agonists.
Med Res Rev. 2019 Jul;39(4):1372-1397. doi: 10.1002/med.21578. Epub 2019 Apr 3.
8
Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype.
ACS Med Chem Lett. 2019 Jan 4;10(2):203-208. doi: 10.1021/acsmedchemlett.8b00551. eCollection 2019 Feb 14.
9
The Disappearing Director: The Case of Directed -Arylation a Removable Hydroxyl Group.
Adv Synth Catal. 2018 Jul 4;360(13):2503-2510. doi: 10.1002/adsc.201701611. Epub 2018 Apr 16.
10
Applications of Palladium-Catalyzed C-N Cross-Coupling Reactions.
Chem Rev. 2016 Oct 12;116(19):12564-12649. doi: 10.1021/acs.chemrev.6b00512. Epub 2016 Sep 30.
本文引用的文献
1
Modification at the Lipophilic Domain of RXR Agonists Differentially Influences Activation of RXR Heterodimers.
ACS Med Chem Lett. 2010 Aug 27;1(9):521-5. doi: 10.1021/ml100184k. eCollection 2010 Dec 9.
2
Feasibility of structural modification of retinoid X receptor agonists to separate blood glucose-lowering action from adverse effects: studies in KKA(y) type 2 diabetes model mice.
Biol Pharm Bull. 2012;35(4):629-33. doi: 10.1248/bpb.35.629.
3
Danthron functions as a retinoic X receptor antagonist by stabilizing tetramers of the receptor.
J Biol Chem. 2011 Jan 21;286(3):1868-75. doi: 10.1074/jbc.M110.166215. Epub 2010 Nov 17.
4
Modification at the acidic domain of RXR agonists has little effect on permissive RXR-heterodimer activation.
Bioorg Med Chem Lett. 2010 Sep 1;20(17):5139-42. doi: 10.1016/j.bmcl.2010.07.012. Epub 2010 Jul 8.
5
Liver X receptor agonists augment human islet function through activation of anaplerotic pathways and glycerolipid/free fatty acid cycling.
J Biol Chem. 2010 Feb 19;285(8):5392-404. doi: 10.1074/jbc.M109.064659. Epub 2009 Dec 11.
6
Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
J Pharmacol Sci. 2009 Oct;111(2):155-66. doi: 10.1254/jphs.09084fp. Epub 2009 Oct 6.
7
Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway.
Biochem Biophys Res Commun. 2009 Apr 24;382(1):51-6. doi: 10.1016/j.bbrc.2009.02.131. Epub 2009 Feb 28.
8
The RXR agonists PA024 and HX630 have different abilities to activate LXR/RXR and to induce ABCA1 expression in macrophage cell lines.
Biochem Pharmacol. 2008 Oct 15;76(8):1006-13. doi: 10.1016/j.bcp.2008.08.005. Epub 2008 Aug 12.
9
Improvement of the transactivation activity of phenylpropanoic acid-type peroxisome proliferator-activated receptor pan agonists: effect of introduction of fluorine at the linker part.
Bioorg Med Chem Lett. 2008 Aug 15;18(16):4525-8. doi: 10.1016/j.bmcl.2008.07.046. Epub 2008 Jul 15.
10
The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4-isopropylphenylamino moiety, NEt-3IP (RXRalpha/beta-dual agonist).
ChemMedChem. 2008 May;3(5):780-7. doi: 10.1002/cmdc.200700313.
Zotero 插件